Sidoti Csr Brokers Cut Earnings Estimates for Assertio Holdings, Inc. (NASDAQ:ASRT)

Assertio Holdings, Inc. (NASDAQ:ASRT) – Research analysts at Sidoti Csr decreased their FY2025 earnings per share estimates for Assertio in a research report issued on Thursday, September 5th. Sidoti Csr analyst J. Sidoti now expects that the company will post earnings of $0.08 per share for the year, down from their previous estimate of $0.19. The consensus estimate for Assertio’s current full-year earnings is ($0.17) per share.

Assertio (NASDAQ:ASRT) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.04) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.02). The firm had revenue of $31.13 million for the quarter, compared to analysts’ expectations of $30.37 million. Assertio had a negative net margin of 261.08% and a positive return on equity of 4.88%. During the same quarter in the prior year, the business earned $0.13 EPS.

ASRT has been the topic of several other reports. HC Wainwright initiated coverage on shares of Assertio in a research report on Wednesday, July 3rd. They set a “buy” rating and a $4.00 target price on the stock. Maxim Group assumed coverage on Assertio in a research note on Friday, July 26th. They issued a “buy” rating and a $3.00 price objective for the company. Alliance Global Partners assumed coverage on Assertio in a report on Tuesday, May 28th. They issued a “buy” rating and a $2.75 target price for the company. Finally, StockNews.com lowered Assertio from a “buy” rating to a “hold” rating in a report on Wednesday, May 15th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $3.44.

Assertio Price Performance

Assertio stock opened at $1.24 on Monday. Assertio has a 52-week low of $0.73 and a 52-week high of $3.19. The company has a quick ratio of 1.51, a current ratio of 1.93 and a debt-to-equity ratio of 0.29. The firm’s fifty day moving average is $1.35 and its 200 day moving average is $1.11. The company has a market cap of $118.22 million, a price-to-earnings ratio of -0.31 and a beta of 0.79.

Institutional Investors Weigh In On Assertio

Several hedge funds and other institutional investors have recently modified their holdings of ASRT. Russell Investments Group Ltd. grew its position in Assertio by 22,096.2% in the 1st quarter. Russell Investments Group Ltd. now owns 2,347,024 shares of the company’s stock valued at $2,251,000 after acquiring an additional 2,336,450 shares during the last quarter. Empowered Funds LLC grew its holdings in shares of Assertio by 8.2% in the first quarter. Empowered Funds LLC now owns 380,417 shares of the company’s stock worth $365,000 after purchasing an additional 28,809 shares during the last quarter. Armistice Capital LLC increased its stake in Assertio by 47.8% in the 4th quarter. Armistice Capital LLC now owns 5,800,000 shares of the company’s stock worth $6,206,000 after buying an additional 1,876,000 shares during the period. Vanguard Group Inc. lifted its holdings in Assertio by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 4,919,614 shares of the company’s stock valued at $4,719,000 after buying an additional 41,071 shares in the last quarter. Finally, SummerHaven Investment Management LLC boosted its position in Assertio by 10.9% in the 2nd quarter. SummerHaven Investment Management LLC now owns 161,171 shares of the company’s stock valued at $200,000 after buying an additional 15,779 shares during the period. 48.96% of the stock is currently owned by hedge funds and other institutional investors.

About Assertio

Assertio Holdings, Inc, a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis.